Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 02 07 2021
revised: 11 11 2021
accepted: 21 11 2021
pubmed: 5 12 2021
medline: 6 5 2022
entrez: 4 12 2021
Statut: ppublish

Résumé

We aimed to compare the outcomes of open vs robotic partial nephrectomy (PN), focusing on predictors of Trifecta failure in patients with highly complex renal masses. We queried the prospectively collected database from the SIB International Consortium, including 507 consecutive patients with cT1-2N0M0 renal masses treated at 16 high-volume referral centres, to select those with highly complex (PADUA score ≥10) tumors undergoing PN. RT was classified as enucleation, enucleoresection or resection according to the SIB score. Trifecta was defined as achievement of negative surgical margins, no acute kidney injury and no Clavien-Dindo grade ≥2 postoperative surgical complications. Multivariable logistic regression analysis was used to assess independent predictors of Trifecta failure. 113 patients were included. Patients undergoing open PN (n = 47, 41.6%) and robotic PN (n = 66, 58.4%) were comparable in baseline characteristics. RT was classified as enucleation, enucleoresection and resection in 46.9%, 34.0% and 19.1% of open PN, and in 50.0%, 40.9% and 9.1% of robotic PN (p = 0.28). Trifecta was achieved in significantly more patients after robotic PN (69.7% vs. 42.6%, p = 0.004). On multivariable analysis, surgical approach (open vs robotic, OR: 2.62; 95%CI: 1.11-6.15, p = 0.027) and tumor complexity (OR for each additional unit of the PADUA score: 2.27; 95%CI: 1.27-4.06, p = 0.006) were significant predictors of Trifecta failure, while RT was not. The study is limited by lack of randomization; as such, selection bias and confounding cannot be entirely ruled out. Tumor complexity and surgical approach were independent predictors of Trifecta failure after PN for highly complex renal masses.

Identifiants

pubmed: 34862095
pii: S0748-7983(21)00935-5
doi: 10.1016/j.ejso.2021.11.126
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

687-693

Informations de copyright

Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence their work.

Auteurs

Riccardo Campi (R)

Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Fabrizio Di Maida (F)

Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Brian R Lane (BR)

Department of Urology, Spectrum Health Medical Group, Grand Rapids, MI, USA.

Ottavio De Cobelli (O)

Department of Urology, European Institute of Oncology (IEO), University of Milan, Milan, Italy.

Francesco Sanguedolce (F)

Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom; Uro-oncology Unit, Fundacio Puigvert, Barcelona, Spain.

Georgios Hatzichristodoulou (G)

Department of Urology, Technical University of Munich, Rechts der Isar University Hospital, Munich, Germany; Department of Urology, Martha-Maria Hospital Nuremberg, Germany.

Alessandro Antonelli (A)

Department of Urology, University of Brescia, Brescia, Italy; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Sabrina Noyes (S)

Department of Urology, Spectrum Health Medical Group, Grand Rapids, MI, USA.

Andrea Mari (A)

Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Antonio Andrea Grosso (AA)

Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Oscar Rodriguez-Faba (O)

Uro-oncology Unit, Fundacio Puigvert, Barcelona, Spain.

Frank X Keeley (FX)

Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom.

Johan Langenhuijsen (J)

Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.

Gennaro Musi (G)

Department of Urology, European Institute of Oncology (IEO), University of Milan, Milan, Italy.

Tobias Klatte (T)

Department of Urology, Royal Bournemouth Hospital, Bournemouth, United Kingdom; Department of Urology, Medical University of Vienna, Vienna, Austria.

Marco Roscigno (M)

Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy.

Bulent Akdogan (B)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Maria Furlan (M)

Department of Urology, University of Brescia, Brescia, Italy.

Nihat Karakoyunlu (N)

Department of Urology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.

Martin Marszalek (M)

Department of Urology and Andrology, Donauspital, Austria; Department of Urology, Graz Medical University, Graz, Austria.

Umberto Capitanio (U)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Milan, Italy.

Alessandro Volpe (A)

Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.

Sabine Brookman-May (S)

Ludwig-Maximilians University (LMU) Munich, Campus Grosshadern, Dept. of Urology, Janssen Pharma Research and Development, Los Angeles, CA, USA.

Jürgen E Gschwend (JE)

Department of Urology, Technical University of Munich, Rechts der Isar University Hospital, Munich, Germany.

Marc C Smaldone (MC)

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Robert G Uzzo (RG)

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Marco Carini (M)

Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Alexander Kutikov (A)

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Andrea Minervini (A)

Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Electronic address: andreamine@libero.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH